Pharmaceutical giant slashes insulin prices after pressure from government and consumers
More than seven million Americans rely on insulin and prices for the life-saving drug have sky-rocketed. With pressure mounting on pharmaceutical companies to address the cost of diabetes care, Eli Lilly announced it’s cutting prices for its most popular insulin products by 70% and capping out-of-pocket costs at $35 a month. Bram Sable-Smith of Kaiser Health News joined Geoff Bennett to discuss.
Stream your PBS favorites with the PBS app: https://to.pbs.org/2Jb8twG
Find more from PBS NewsHour at https://www.pbs.org/newshour
Subscribe to our YouTube channel: https://bit.ly/2HfsCD6
PBS NewsHour podcasts: https://www.pbs.org/newshour/podcasts